1.. Introduction
================

HCoV-NL63 was identified in 2004 in a child with bronchiolitis in The Netherlands \[[@b1-viruses-01-00647]\], yet worldwide screenings revealed that the virus can be detected throughout the globe in children and adults with respiratory tract infections \[[@b2-viruses-01-00647]--[@b8-viruses-01-00647]\]. People acquire their first infection with HCoV-NL63 early in life \[[@b9-viruses-01-00647]\], and during this first infection the chance to develop larynchotracheabronchitis (croup) is high \[[@b10-viruses-01-00647]\]. With increasing age people experience repeated infections (unpublished findings LvdH), and in case of underlying disease an HCoV-NL63 infection can require hospitalization. On the whole we can say that within a few years a vast amount of data on this new virus has become available, except that the pathogenesis of HCoV-NL63 remains unknown. The lacking of an animal model system is the problem. In addition, an animal model system is needed to fulfill the Koch's postulates and link infection to a disease.

To date, only a limited number of primary or immortalized cells from either human or non-human primate origin support propagation of HCoV-NL63 \[[@b1-viruses-01-00647],[@b11-viruses-01-00647]--[@b13-viruses-01-00647]\]. The first HCoV-NL63 isolate that was cultured was propagated on tertiary monkey kidney cells of a cynomolgus monkey (latin: *Macaca fascicularis*) and subsequently passaged to LLC-MK2 cells, a cell line derived from the kidney of a rhesus macaque (latin: *Macaca mulatta*). It is of interest to investigate whether rhesus macaques can be infected by HCoV-NL63. This can either be investigated by direct inoculation of Rhesus Macaque with HCoV-NL63. Alternatively, one can establish whether rhesus macaques that are in close contact to humans have experienced a natural HCoV-NL63 infection by investigating the NL63-directed antibody titers in time.

2.. Results and Discussion
==========================

A sudden rise in coronavirus antibody titers is a strong indication for a coronavirus infection. We have shown this for children who acquire their first HCoV-NL63 infection during their first years of life \[[@b9-viruses-01-00647]\]. At later ages repeated infections with human coronaviruses can occur \[[@b14-viruses-01-00647]\], depending on the levels of protective antibodies. Protective antibodies peak shortly after infection and gradually decrease during the following years, with accompanying susceptibility to a reinfection with time. In the current study we use the kinetics of the antibody response to HCoV-NL63 to determine whether rhesus macaques encounter natural infections with HCoV-NL63, or related coronaviruses. The serological assays were performed with the N-protein of HCoV-NL63 which is an immunodominant protein, although there is some homology with the N-protein of the closest relative of HCoV-NL63, HCoV-229E. To ascertain the most specificity, the C-terminal region (amino acids 215 to 377) of the protein -- which has the most difference between NL63-N and 229E-N - was used. In addition competition experiments with homologous and heterologous proteins were included in each experiment to ascertain the specificity of an antibody response.

The first indication of infections with HCoV-NL63-like viruses in rhesus macaques was found when we tested 32 serum samples of 32 monkeys ([Table 1](#t1-viruses-01-00647){ref-type="table"} and [Figure 1](#f1-viruses-01-00647){ref-type="fig"}). Five samples showed high levels of antibodies to the HCoV-NL63 protein. The same samples did not have elevated levels of antibodies to HCoV-229E, indicative that the response was specific (data not shown). Furthermore, competition experiments with the NL63-protein and the 229E-protein revealed that only the homologous protein could compete with binding to the NL63-protein on the ELISA plate (data not shown), suggesting that the antibodies are directed to an HCoV-NL63-like virus.

Longitudinal serum samples were available of three rhesus macaques with the highest antibody levels to HCoV-NL63 (numbers 5, 10 and 17). These monkeys had been sampled on a regular basis, with on average one serum sample every one or two years. Sampling started when the macaques were already a few years old, except for one which was followed from 6 months of age. In all three animals a sudden rise in antibody titers was noticed ([Figure 2](#f2-viruses-01-00647){ref-type="fig"}, panel A, B and C). Rhesus macaque number 5 was followed from 1989 (starting at the age of 6 years) with high levels of NL63-directed antibodies. A strong peak was observed in 2003, indicating that the animal experienced an additional HCoV-NL63 infection (at 20 years of age). Animal number 10 started with low titers to HCoV-NL63 (age 2 years) but after some years very high titers to HCoV-NL63 were visible (age 8 years). Unexpectedly, these high antibody levels remained for the complete follow-up period (last sample collected at the age of 13). This is suggesting that the adaptive immune response to HCoV-NL63 is constantly activated, and one could speculate that this animal is experiencing a chronic HCoV-NL63 infection. Unfortunately, additional samples like throat swabs or faeces to test for chronic infections were not available. The third animal (number 17) was followed from early age on, starting with low levels of NL63-antibodies. Between the years 2003/2004 a steep rise in antibody levels was noted, whereas a second rise occurred after the winter of 2006/2007 (at 4 years and almost 7 years of age respectively). The animals were all checked for antibodies to HCoV-229E, but for none of the three monkeys reactivity was detected ([Figure 2](#f2-viruses-01-00647){ref-type="fig"}). This is in accordance with the first screening of the animals, which already showed low levels of HCoV-229E antibodies in these animals.

To confirm our findings we determined whether the post-seroconversion samples also react with whole virus by performing an immunofluorescence assay with HCoV-NL63 infected cells. In all cases with low HCoV-NL63 antibodies we saw no reactivity with the infected cells. Whereas all samples obtained after seroconversion showed clear reactivity with whole virus (shown for animal number 10 in [Figure 3](#f3-viruses-01-00647){ref-type="fig"}).

With the assay used we cannot obtain evidence that it were HCoV-NL63 infections that these monkeys have encountered. However, one can conclude that it were infections with HCoV-NL63, or a virus which is serologically closely related. It can never be excluded that there is a coronavirus infecting these rhesus monkeys that is closely related to HCoV-NL63 (but has not been identified yet). Sampling of the respiratory tract on a regular basis throughout the years and eventually identify the pathogen that is eliciting the antibody response can answer this question, but is not an easy task. To our opinion the most likely explanation would be that natural infection with HCoV-NL63 occurs. The macaques described in this study live in a closed system with close contacts to humans (feeding, cleaning of cages, *etc*.). Through this contact they can encounter the virus as infections of humans with HCoV-NL63 occurs frequently in winter seasons \[[@b10-viruses-01-00647]\]. As the cells of this monkey species are susceptible to infection (LLC-MK2 cells, a kidney epithelial cell line) it is very likely that *in vivo* infections can occur as well.

The animals of our study were clinically examined on a routine yearly basis for colony health surveillance, but subclinical infections with coronaviruses will go unnoticed during this check up and in the periods between the examinations. Thus it can not be determined whether the seroconversion or reconversion to HCoV-NL63 was accompanied with minor clinical signs. Future studies should be designed to investigate viral infection with human viruses and the accompanying clinical signs to further unravel this subject. Here we show that it is not necessary to sacrifice monkeys by experimental infecting. A well-designed follow up through the years with serum and respiratory samples collected on a regular basis would be sufficient to unravel the potential of the human respiratory viruses to infect rhesus macaques. Once a cohort has set up and samples have been collected for a few years, all newly identified respiratory viruses can be screened with the appropriate serological assays, and infection related to clinical symptoms.

Natural infections of rhesus macaques with viruses that are known to be of human origin are not unusual. It has been described that smallpox, measles, rubella or parainfluenzavirus 1 and 2 cause natural infection of Rhesus macaques and the closely related cynomolgus macaques \[[@b15-viruses-01-00647],[@b16-viruses-01-00647]\]. Furthermore, experimental infection with several viruses showed that the animals are susceptible to various human respiratory viruses like respiratory syncytial virus and SARS coronavirus \[[@b17-viruses-01-00647],[@b18-viruses-01-00647]\]. With the knowledge that natural infection of HCoV-NL63 is likely to occur, one should keep in mind that this has implications for animal model experiments. In case rhesus macaques are experimentally infected with HCoV-NL63 this might be a reinfection, in case the animal has encountered the virus previously, or the first infection, in case the animal is still young and was not naturally infected through human contact. The clinical signs during the first infection might be of a more severe nature in comparison with a recurrent infection. This should be taken into account in case a study is conducted to reveal the pathogenesis of the virus in an animal model system.

3.. Experimental Section
========================

Serum of Rhesus Macaque monkeys
-------------------------------

Cross-sectional and longitudinal serum specimens were collected from Rhesus macaques with an Indian, Burmese or Chinese genetic background. The Rhesus macaques were either imported or born in The Netherlands in one of the breeding colonies. The animals have not been isolated but remained in a breeding colony and were not used for immunization with antigens or adjuvant, or any other study. All serum specimens were stored at −80°C and heat-inactivated at 56°C for 30 minutes prior to analysis.

Generation and expression of recombinant HCoV-NL63 and HCoV-229E carboxyl-terminal nucleocapsid proteins
--------------------------------------------------------------------------------------------------------

The generation of the plasmid construct was performed as described \[[@b9-viruses-01-00647]\]. For HCoV-NL63 the following primer combination was used 5′ NL63_N5_CT (5′ -- CACCAAACCTAATAAGCCTCT TTCTCAAC -- 3′) and 3′ NL63_Nexp (5′ -- TTAATGCAAAACCTCGTTGAC -- 3′), whereas for HCoV-229E the primer combination 5′ 229E_5N_CT (5′ -- CACCCCTTCTCGTAATCAGAGTCCT -- 3′) and 3′ 229E_Nexp (5′ -- TTAGTTTACTTCATCAATTAT -- 3′) was used. The generated pET100_NL63_CT and pET100_229E_CT plasmids were sequenced and shown to be 100% identical to the virus reference sequences of HCoV-NL63 (Amsterdam-01) and HCoV-229E (Inf-1), respectively. Subsequent expression and purification of the HCoV-NL63 and HCoV-229E recombinant carboxyl-terminal nucleocapsid proteins was performed as previously described \[[@b9-viruses-01-00647]\].

Carboxyl-terminal nucleocapsid ELISA
------------------------------------

Ninety-six-well ELISA plates (Greiner Bio-one) were coated overnight at 4°C with 3 μg/ml of expressed recombinant C-terminal N protein of HCoV-NL63 or HCoV-229E. The proteins were diluted in 0.1 M carbonate buffer pH 9.6. Unspecific binding sites were blocked with PBS + 0.1% Tween20 (PBST) supplemented with 5% skim milk (Fluka) for one hour at room temperature (RT). Longitudinal and cross-sectional sera were diluted 1:200, in PBST containing 1% skim milk and incubated on the plate for 2 hours at RT. After washing, Alkaline Phosphatase conjugated anti-monkey IgG antibody (Sigma Aldrich) diluted (1:40,000) in 1% skim milk PBST was added. Following one hour at RT the plates were washed and signal was developed with 50 μl of Lumi-Phos Plus (Lumigen). Measurements were done with a Glomax™ 96 Plate Luminometer (Promega). All sera were tested in duplicate.

Carboxyl-terminal nucleocapsid competition ELISA
------------------------------------------------

Rhesus Macaque sera were diluted (1:200) in PBST containing 1% skim milk and twofold serial dilutions ranging from 50 to 0 μg/ml of either expressed recombinant C-terminal N protein of HCoV-NL63, N protein of HCoV-229E or LacZ protein and incubated for 1 hour at RT. Prior to incubation, the mixtures were briefly homogenized by vortexing. No centrifugation was performed. Following the pre-incubations the samples were measured by HCoV-NL63 or HCoV-229E ELISA, as described above.

Immunofluorescence on HCoV-NL63 infected cells
----------------------------------------------

LLC-MK2 cells were seeded on coverslips in 12-well plates at a density of 0.32 × 106 cells / well and cultured at 37 °C with 5% CO2 in minimal essential medium (MEM; 2 parts Hanks' MEM and 1 part Earle's MEM) supplemented with 3% heat-inactivated fetal calf serum (PAA Laboratories), penicillin (100 U/ml), and streptomycin (100 μg/ml). Cells were infected with HCoV-NL63 at a multiplicity of infection of 0.007 and incubated at 37 °C with 5% CO2. After 4 days cells were fixated with 3.7% PFA in PBS for 30 minutes at room temperature (RT). The unspecific binding sites were blocked overnight at 4 °C with incubation buffer (2 % BSA (Sigma Aldrich) in PBS with 0.1% saponin and 50 mM ammonium chloride). For detection of HCoV-NL63 proteins cells were double stained for 1 hour at RT in incubation buffer with rabbit derived anti-S1-NL63 sera (1:200) and Rhesus macaque sera (1:100) as primary antibodies. Donkey derived, Dylight 649 labeled, anti-rabbit IgG (H+L) and donkey derived, Dylight 594 labeled, anti-human IgG (H+L) (1:200) (Jackson immunoresearch) were applied as secondary antibodies for 1 hour at RT in incubation buffer, followed by nuclear DNA staining with Hoechst 33528. Fluorescent images were acquired on a Leica TCS SP2 AOBS spectral confocal microscope with a 63x HCX PL APO 1.32 oil objective.

4.. Conclusions
===============

In the early days of human coronavirus identification (the 1960s) it was possible to experimentally infect volunteers with the viruses which were isolated from persons with common colds. Nowadays, with the recent epidemic of SARS-CoV, it is very difficult to attract volunteers for such studies. Not only has the public become aware of the potential dangers of a coronavirus infection, the recently identified viruses (HCoV-NL63 and HCoV-HKU1) have been isolated from children or adults with severe lower respiratory tract infection, and not simple common colds. Consequently, the only possibility to connect the recently identified coronaviruses to a certain disease is via associations with disease or animal experiments. To date no animal model system has been described for HCoV-NL63. Although all signs suggest that Rhesus macaques might be a good model system -- since cells of Rhesus macaques can be *in vitro* infected by HCoV-NL63 -- nobody has reported infection of these animals yet. We show here that there are clear signs that Rhesus macaques acquire natural infections with HCoV-NL63, or a serologically very closely related coronavirus. In future animal experiments to be carried out with Rhesus macaques the history of an animal should be known to determine whether the experimental infection occurs in an HCoV-NL63 naïve animal or an animal that has encountered the virus during life, as clinical symptoms might differ greatly in first or recurrent infection.
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![Antibody levels to HCoV-NL63. On the X-axis the Rhesus Macaque ID is indicated. On the Y-axis relative luminescence signal (RLU) in an ELISA detecting antibodies to the C-terminal nucleocapsid protein is shown. Rhesus macaques of which longitudinally collected serum samples were analyzed are indicated with a "\*".](viruses-01-00647f1){#f1-viruses-01-00647}

![Serological response to HCoV-NL63 and HCoV-229E in time. Reactivity to the C-terminal nucleocapsid protein of HCoV-NL63 is shown as closed circles (continuous line), to the HCoV-229E C-terminal nucleocapsid protein closed squares (dashed line). (a) Rhesus Macaque 5; (b) Rhesus Macaque 10; (c) Rhesus Macaque 17. The X-axis displays the age in years of the Rhesus Macaque during follow up, the Y-axis the relative luminescence signal (RLU) in the two C-terminal nucleocapsid protein antibody ELISAs.](viruses-01-00647f2){#f2-viruses-01-00647}

![Immunofluorescence detection of HCoV-NL63 in infected LLC-MK2 cells. Reactivity of rhesus macaque number 10 sera towards HCoV-NL63 infected (HCoV-NL63 positive) and non-infected (control) LLC-MK2 cells, at the age of 6 (preseroconversion) and 8 (postseroconversion) years. The images represent the cell nucleus (blue) and rhesus macaque antibodies (green) signals.](viruses-01-00647f3){#f3-viruses-01-00647}

###### 

Demographic characteristics of the Rhesus macaques included in HCoV-NL63 antibody analysis.

  **Rhesus Macaque ID**   **Sampling date**   **Date of birth**   **Genetic origin**
  ----------------------- ------------------- ------------------- --------------------
  1                       17-4-2008           26-3-1983           India
  2                       24-4-2008           11-12-2000          India
  3                       29-9-2008           4-5-1982            India
  4                       29-9-2008           6-7-1983            India
  5                       29-9-2008           16-10-1983          India
  6                       6-10-2008           1-1-1996            Burma
  7                       6-10-2008           9-8-1996            Burma
  8                       6-10-2008           12-4-1989           Burma
  9                       20-10-2008          6-4-2001            India
  10                      27-10-2008          7-5-1995            Burma
  11                      15-8-2007           7-1-1995            China
  12                      15-8-2007           14-4-1995           China
  13                      17-4-2007           20-9-1994           China
  14                      17-4-2007           16-6-1994           China
  15                      3-4-2008            6-8-1980            India
  16                      10-4-2008           24-4-2000           India
  17                      10-4-2008           1-5-2000            India
  18                      10-4-2008           20-5-1995           Burma
  19                      14-4-2008           3-12-1988           Burma
  20                      14-4-2008           31-12-1988          Burma
  21                      27-10-2008          12-1-1997           Burma
  22                      27-10-2008          26-1-1997           Burma
  23                      12-1-2009           4-1-1996            India
  24                      12-1-2009           11-3-1996           India
  25                      5-1-2009            11-3-2000           India
  26                      29-12-2008          9-4-2001            India
  27                      29-12-2008          13-3-2000           India
  28                      13-1-2009           26-9-1995           Burma
  29                      24-8-2000           5-2-1995            China
  30                      30-1-2003           24-4-1995           China
  31                      8-5-2006            27-12-1994          China
  32                      4-2-2002            23-3-1995           China
